<p>Despite missense mutation accounts for over 60% of <i>p53</i> alterations while homozygous deletion (HOM) for only 5% or less in advanced bladder cancer cases, most of the previously reported mouse models are deficient of p53. Accordingly, few studies have addressed the mechanisms of missense mutation occurrence and its functional advantage over HOM in bladder cancer development. Organoids derived from Krt5-expressing mouse urothelium (K5-mUrorganoid) demonstrated the crucial role of <i>Pten</i> loss in driving loss of wild-type allele of <i>Trp53</i> (<i>Trp53</i><sup><i>R172H/LOH</i></sup>), which conferred tumorigenic ability to K5-mUrorganoid in athymic mice. These tumors recapitulated the histological and genetic characteristics of the human basal-squamous subtype bladder cancer. Both <i>Trp53</i><sup><i>R172H/Δ</i></sup><i>; Pten</i><sup><i>Δ/Δ</i></sup> and <i>Trp53</i><sup><i>Δ/Δ</i></sup><i>; Pten</i><sup><i>Δ/Δ</i></sup> K5-mUrorganoids formed tumors in athymic mice, whereas only <i>Trp53</i><sup><i>R172H/Δ</i></sup><i>; Pten</i><sup><i>Δ/Δ</i></sup> K5-mUrorganoid formed tumors even when directly inoculated in immunocompetent syngeneic mice. The absence of wild-type <i>Trp53</i> was associated with upregulation of proliferative signaling, and the presence of a mutant <i>Trp53</i> allele was associated with immune-excluded microenvironment. This study highlights the functional significance of <i>p53</i> mutant LOH in bladder carcinogenesis conferring several hallmarks of cancer such as sustaining proliferative signaling and avoiding immune destruction, thus provides a novel immunocompetent mouse model of urothelial carcinoma harboring <i>p53</i> mutations as a novel tool for cancer immunology research.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

PTEN loss drives p53 LOH and immune evasion in a novel urothelial organoid model harboring p53 missense mutations

  • Akihiro Hamada,
  • Yuki Kita,
  • Toru Sakatani,
  • Kenji Nakamura,
  • Hideaki Takada,
  • Ryosuke Ikeuchi,
  • Shuhei Koike,
  • Norihiko Masuda,
  • Kaoru Murakami,
  • Takeshi Sano,
  • Takayuki Goto,
  • Ryoichi Saito,
  • Yuki Teramoto,
  • Masakazu Fujimoto,
  • Narumi Hatano,
  • Mayumi Kamada,
  • Osamu Ogawa,
  • Takashi Kobayashi

摘要

Despite missense mutation accounts for over 60% of p53 alterations while homozygous deletion (HOM) for only 5% or less in advanced bladder cancer cases, most of the previously reported mouse models are deficient of p53. Accordingly, few studies have addressed the mechanisms of missense mutation occurrence and its functional advantage over HOM in bladder cancer development. Organoids derived from Krt5-expressing mouse urothelium (K5-mUrorganoid) demonstrated the crucial role of Pten loss in driving loss of wild-type allele of Trp53 (Trp53R172H/LOH), which conferred tumorigenic ability to K5-mUrorganoid in athymic mice. These tumors recapitulated the histological and genetic characteristics of the human basal-squamous subtype bladder cancer. Both Trp53R172H/Δ; PtenΔ/Δ and Trp53Δ/Δ; PtenΔ/Δ K5-mUrorganoids formed tumors in athymic mice, whereas only Trp53R172H/Δ; PtenΔ/Δ K5-mUrorganoid formed tumors even when directly inoculated in immunocompetent syngeneic mice. The absence of wild-type Trp53 was associated with upregulation of proliferative signaling, and the presence of a mutant Trp53 allele was associated with immune-excluded microenvironment. This study highlights the functional significance of p53 mutant LOH in bladder carcinogenesis conferring several hallmarks of cancer such as sustaining proliferative signaling and avoiding immune destruction, thus provides a novel immunocompetent mouse model of urothelial carcinoma harboring p53 mutations as a novel tool for cancer immunology research.